Electromed, Inc. a leader in innovative airway clearance technologies, announced its launch of the SmartVest® Clearway® Airway Clearance System to the hospital market for inpatient use. The SmartVest Clearway system, which is designed for High Frequency Chest Wall Oscillation (“HFCWO”) therapy, offers an updated and efficient approach to pulmonary hygiene in the inpatient setting with proven patient outcomes.1
The SmartVest Clearway system uses HFCWO, a clinically proven therapy that helps clear the lungs of excess secretions, thereby reducing the risk of respiratory infections.1 HFCWO delivers alternating pulses of air into a vest garment that rapidly compresses and releases the chest wall, resulting in an oscillation in airflow within the airways that acts to loosen, thin, and propel mucus toward the major airways where it can be expectorated.
“SmartVest Clearway provides therapeutic relief for patients suffering from ineffective secretion clearance due to muscle weakness, ineffective cough, or impaired ventilation. The intuitive system is designed to help hospital staff speed patient recovery for patients with dysfunctional airway clearance,” commented Jim Cunniff, President and Chief Executive Officer of Electromed. “We are proud to further our mission in assisting more patients to breathe easier, improve their quality of life, and prevent hospital readmissions.”
About Electromed, Inc.
Electromed manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota and founded in 1992. Further information about Electromed can be found at www.smartvest.com.
Cautionary Statements
Certain statements in this press release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “assume,” “believe,” “expect,” “may,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for the Company include, but are not limited to, the duration, extent and severity of the COVID-19 pandemic, including its effects on our business, supply chain, operations and employees as well as its impact on our customers and distribution channels and on economies and markets more generally; the competitive nature of our market; changes to Medicare, Medicaid, or private insurance reimbursement policies; changes to state and federal health care laws; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the homecare distributor channel; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; new drug or pharmaceutical discoveries; general economic and business conditions; our ability to renew our line of credit or obtain additional credit as necessary; our ability to protect and expand our intellectual property portfolio; the risks associated with expansion into international markets, as well as other factors we may describe from time to time in the Company’s reports filed with the Securities and Exchange Commission (including the Company’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.
1 Sievert CE, et al. 2016. Respiratory Therapy, 11(4), 34–38.
Contacts
Brad Nagel, Chief Financial Officer
(952) 758-9299
investorrelations@electromed.com
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641